CAR T-Cell Therapy Market

CAR T-Cell Therapy Market By Product (Yescarta [axicabtagene ciloleucel], Kymriah [tisangenlecleucel], JCAR017 [lisocabtagene maraleucel], bb2121), By Indication (Relapsed Large B-cell Lymphoma, Acute Lymphoblastic Leukemia (ALL), Multiple Myeloma), By End User (Hospitals, Cancer Treatment Centers) and By Region – Global Market Report (2024 to 2034)

Analysis of CAR T-Cell Therapy Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

CAR T-Cell Therapy Market Outlook (2024 to 2034)

The global CAR T-cell therapy market size is estimated at a value of US$ 2.25 billion in 2024 and is projected to reach US$ 11.49 billion by the end of 2034, expanding at a CAGR of 17.7% over the next ten years (2024 to 2034).

The topic of cell therapy technologies is a vast area of science and medicine that focuses on replacing, enhancing, or repairing damaged tissues, cells, or organs. This sector is changing quickly due to major advances in technology and research.

Although CAR T-cell (chimeric antigen receptor T-cell) therapies have the potential to revolutionize cancer care, they are now limited to patients with certain liquid malignancies that have relapsed and are not responding to treatment. Gene therapy is a groundbreaking and rapidly evolving field of medicine that involves modifying a person's genes to treat or prevent disease.

Investment is required in four areas to fully realize the potential of CAR T-cells. Refining autologous CAR T-cells for liquid tumors, increasing the number of healthcare settings where CAR T-cells are administered, reducing the time it takes to innovate to enable success in solid tumors, and developing novel manufacturing techniques for next-generation CAR T-cell therapies.

Since 2017, significant scientific progress has resulted in three CAR T-cell approvals for DLBCL and ALL. Selected relapsed or refractory liquid tumors, which affect fewer than 5% of cancer patients today, are the target of approved CAR T-cell therapy. Over 500 trials with novel CAR T-cell treatments were active in 2019 due to the pipeline's quick expansion. Although CD19 was the target of the first CAR T-cell research, a greater variety of targets and tumor types are now included in clinical programs.

B-cell maturation antigen (BCMA), a prevalent cell surface antigen in multiple myeloma, and several other cell surface antigens are the targets of additional CAR T-cells. The clinical data has been the driving force for the industry's increased interest in CAR T-cells.

Report Attributes Details
CAR T-Cell Therapy Market Size (2024E) US$ 2.25 Billion
Forecasted Market Value (2034F) US$ 11.49 Billion
Global Market Growth Rate (2024 to 2034) 17.7% CAGR
North America Market Share (2034F) 59.4%
Western Europe Market Growth Rate (2024 to 2034) 18.7% CAGR
Yescarta (Axicabtagene Ciloleucel) Market Share (2024E) 52.6%
Market Share of Cancer Treatment Centers (2024E) 92.6%
Key Companies Profiled
  • Autolus Therapeutics
  • 2Seventy Bio, Inc.
  • Bristol-Myers Squibb
  • Pfizer
  • Gilead Sciences
  • Intellia Therapeutics
  • Caribou Biosciences, Inc.
  • Cartesian Therapeutics, Inc.
  • Novartis AG

Don't Need a Global Report?

save 40%! on Country & Region specific reports

Which Key Factors are Driving Global Demand for CAR T-Cell Therapy?

“Rising Cancer Incidence and Robust Product Pipelines”

Strong product pipelines and rising cancer incidence are projected to fuel the CAR T-cell therapy market growth.

  • According to the World Health Organization (WHO), one in five individuals is expected to experience cancer during their lifetime, with one in eight men and one in eleven women succumbing to the disease.
  • Almost 50 million people are still alive after receiving a cancer diagnosis five years ago. The WHO estimates that there were about 544,352 new cases of non-Hodgkin lymphoma reported worldwide in 2020.

A strong product pipeline is largely responsible for the rising demand for CAR T-cell therapy products.

  • One cutting-edge therapy for adult acute lymphoblastic leukemia, AUTO1, is being tested in a phase I trial by Autolus Therapeutics. Obecabtagene autoleucel is an experimental CD19 CAR T-cell therapy found in AUTO1, which is intended to address the shortcomings of existing CD19 CAR T-cell therapies in terms of safety and clinical activity.

"Shift in Focus to Adoptive Therapy Driving Competition and Investments”

With many organizations shifting from traditional small chemical and protein-based medicines to adoptive therapy, the landscape of therapeutic development has changed significantly. The approval of ground-breaking treatments like Tecartus, Yescarta, and Kymriah has sparked this change and ushered in a new era in cancer treatment. The market for T-cell treatment has seen a surge in strategic investments from both public and commercial entities due to the significant impact of these breakthroughs.

  • For example, Yescarta is the first chimeric antigen receptor (CAR) T-cell treatment approved by the United States FDA in February 2022 for the initial management of relapsed or refractory large B-cell lymphoma (LBCL).

The NCCN Treatment Guidelines have classified Yescarta as the first CAR T-cell treatment to receive a Category 1 recommendation. Similarly, the FDA approved ciltacabtagene autoleucel (Carvykti) in February 2022 for patients with refractory multiple myeloma, that is, those who have not responded to treatment or have returned after treatment (relapsed).

What are the Challenges Encountered by Market Players?

“Excessive Treatment Costs and Complicated Manufacturing Process”

CAR T-cell treatments are very costly, frequently requiring several hundred thousand dollars for each session. This expensive price point puts a heavy load on healthcare systems and insurers while potentially limiting patient accessibility.

It takes a lot of time and effort to produce CAR T-cell treatments. It entails customized manufacturing for every patient, which may cause administrative difficulties and therapeutic delays.

“Reimbursement Challenges and Restricted Range of Treatment”

Insurance companies and government health programs may find it difficult to fund CAR T-cell therapies due to their high cost. Disparities in treatment access may result from this.

As of now, solid tumors can be treated with limited success using CAR T-cells, primarily applied in the treatment of certain blood malignancies. This limits the group of patients who may potentially benefit from these treatments.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Country-wise Insights

The United States is projected to occupy a leading CAR T-cell therapy market share by 2034, as a result of the rise in cancer incidence and increasing number of clinical trials involving CAR T-cells. Through 2034, the Europe market is forecasted to grow at a significant pace. This is attributed to several factors, such as a large and diverse population, advancements in healthcare facilities, and a rise in the elderly population, which is more vulnerable to cancer.

Why is the United States a Lucrative Market for CAR T-cell Therapy Providers?

"Increasing Healthcare Investments and High-Level Oncological Research and Development”

Attribute United States
Market Value (2024E) US$ 1.39 Billion
Growth Rate (2024 to 2034) 16.6% CAGR
Projected Value (2034F) US$ 6.46 Billion

Rising prevalence of chronic illnesses like cancer and autoimmune disorders, the increase in research and development activities, and the presence of powerful and well-established market competitors are key market drivers in the United States. The industry is growing as a result of the increasing number of investments. The growth of the United States market is primarily due to the strong presence of major companies in the area and the high level of research and development being done to create novel CAR T-cell therapies.

  • In June 2021, Blackstone Life Sciences, alongside Intellia Therapeutics, Inc., and Cellex Cell Professionals GmbH, a clinical-stage cell therapy company, announced a commitment of US$ 250 million to establish a novel autologous and allogeneic universal chimeric antigen receptor (CAR) T-cell therapy company.

What’s Drawing CAR T-Cell Therapy Providers to Germany?

“Well-established Healthcare Infrastructure and Stringent Patient Safety Regulations”

Attribute Germany
Market Value (2024E) US$ 202 Million
Growth Rate (2024 to 2034) 19.3% CAGR
Projected Value (2034F) US$ 1.18 Billion

Germany has a well-established healthcare system, which is essential for providing advanced therapies like CAR T-cell therapy. German cancer treatment facilities and hospitals are staffed with highly qualified professionals who are competent to deliver these cutting-edge procedures.

National and European Union regulations form the foundation of Germany's regulatory environment. These rules, designed to ensure patient safety and treatment efficacy, govern the approval and reimbursement procedures for novel medicines, including CAR T-cell therapy.

Factors driving market expansion include an increase in research and clinical trials, a rise in awareness, and a spike in pharmaceutical and biotechnology investments for the creation of novel pharmaceuticals.

Category-wise Insights

Market growth is projected to be influenced by an increase in demand for Yescarta (axicabtagene ciloleucel) in the treatment of follicular lymphoma and diffuse large B-cell lymphoma. Due to the availability of a broad range of treatment options and the rise in the number of cancer treatment centers in several emerging countries, the industry for cancer treatment centers is forecasted to grow at a substantial pace through 2034.

Which Product is Widely Adopted for CAR T-Cell Therapy?

“Extensive Use of Yescarta in Treatment of Specific Blood Malignancies"

Attribute Yescarta (Axicabtagene Ciloleucel)
Segment Value (2024E) US$ 1.18 Billion
Growth Rate (2024 to 2034) 17.4% CAGR
Projected Value (2034F) US$ 5.91 Billion

'Yescarta' (axicabtagene ciloleucel) is a prominent product, especially for the treatment of certain blood malignancies. Yescarta, created by Gilead subsidiary Kite Pharma, has significantly changed the field of cancer immunotherapy. Yescarta was approved by the United States FDA in October 2017 for use in adult patients with relapsed or refractory follicular lymphoma (FL) following two or more rounds of systemic therapy.

After two or more lines of systemic therapy, adult patients with specific forms of non-Hodgkin lymphomas, including those with relapsed or refractory large B-cell lymphomas, can be treated with Yescarta. Diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and DLBCL resulting from follicular lymphoma are examples of this.

Which End User Accounts for a Massive Share of the Market?

“Cancer Treatment Centers Playing Crucial Role in Efficient Patient Evaluation and Monitoring”

Attribute Cancer Treatment Centers
Segment Value (2024E) US$ 2.08 Billion
Growth Rate (2024 to 2034) 17.7% CAGR
Projected Value (2034F) US$ 10.65 Billion

Since CAR T-cell therapy is typically used after other therapies have failed, cancer treatment facilities that use it are in charge of choosing their patients. They are also essential in patient evaluation prior to treatment, patient monitoring during treatment, and long-term patient follow-up.

A large number of these centers are also engaged in CAR T-cell therapy research and clinical trials. They are also engaged in investigating new indications, testing new medicines, and enhancing treatment regimens.

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Competitive Landscape

The market is highly competitive, with a dynamic and fast-changing landscape characterized by intense R&D, strategic partnerships, and an emphasis on innovation to overcome current obstacles. Biotechnology and pharmaceutical firms stand out as major contenders in this market, as they lead the development and commercialization of CAR T-cell therapy.

  • Autolus Therapeutics plc launched in May 2023 the pivotal Phase 2 FELIX investigation of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult B-cell acute lymphoblastic leukemia (ALL). The abstract of this study was selected for an oral presentation at the 2023 Congress of the European Hematology Association (EHA).

Segmentation of CAR T-Cell Therapy Market Research

  • By Product :

    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • JCAR017 (Lisocabtagene Maraleucel)
    • bb2121
  • By Indication :

    • Relapsed Large B-cell Lymphoma
    • Acute Lymphoblastic Leukemia (ALL)
    • Multiple Myeloma
  • By End User :

    • Hospitals
    • Cancer Treatment Centers
  • By Region :

    • North America
    • Latin America
    • Europe
    • East Asia
    • South Asia & Oceania
    • Middle East & Africa

- FAQs -

What is the size of the CAR T-cell therapy market in 2024?

The global Car T-cell therapy market is estimated at US$ 2.25 billion in 2024.

What is the projected revenue from CAR T-cell therapy solutions by the end of 2034?

By 2034-end, worldwide revenue from CAR T-cell therapy is forecasted to reach US$ 11.49 billion.

How fast is the demand for CAR T-cell therapy forecasted to rise?

Demand for CAR T-cell therapy is forecasted to rise at 17.7% CAGR over the next 10 years.

What is the sales projection for CAR T-cell therapy in Western Europe?

Sales of CAR T-cell therapy solutions in Western Europe are projected to increase at 18.7% CAGR from 2024 to 2034.

At what rate is the use of CAR T-cell therapy projected to rise in cancer treatment centers?

Use of CAR T-cell therapy in cancer treatment centers is forecasted to rise at a CAGR of 17.7% from 2024 to 2034.

- Also of Interest -

Cell Line Development Market

Cell Line Development Market Analysis by Immunotherapy Cell Lines, Ion Channel Cell Lines, and GPCR Cell Lines from 2023 to 2033

Cell Therapy Technologies Market

Cell Therapy Technologies Market Study by Media, Sera & Reagents, Cell Engineering, Cell Culture Vessels, Cell Therapy, Cell Processing, Single-use Equipment, and Systems & Software from 2023 to 2033

Gene Therapy Market

Gene Therapy Market Study by Lentivirus, Adeno-Associated Virus, Retrovirus & Gamma Retrovirus, Modified Herpes Simplex Virus, Adenovirus, Non-viral Plasmid Vector from 2024 to 2034

CAR T-Cell Therapy Market

Schedule a Call